Prothena Corporation plc (NASDAQ:PRTA) Receives Average Rating of “Hold” from Brokerages

Prothena Corporation plc (NASDAQ:PRTA) has earned a consensus rating of “Hold” from the eleven ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $22.00.

Several brokerages have commented on PRTA. Chardan Capital raised Prothena to a “strong-buy” rating in a research report on Wednesday, November 19th. Wall Street Zen upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. HC Wainwright lifted their price target on shares of Prothena from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Prothena in a research note on Monday, December 1st. Finally, Citizens Jmp set a $19.00 price objective on shares of Prothena in a report on Monday, December 1st.

Institutional Trading of Prothena

A number of large investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Prothena in the fourth quarter worth $414,000. XTX Topco Ltd lifted its holdings in Prothena by 247.2% in the fourth quarter. XTX Topco Ltd now owns 54,881 shares of the biotechnology company’s stock valued at $524,000 after acquiring an additional 39,073 shares during the period. Virtus Investment Advisers LLC boosted its position in Prothena by 14.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 25,679 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 3,236 shares during the last quarter. Susquehanna Portfolio Strategies LLC grew its stake in shares of Prothena by 103.1% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 58,853 shares of the biotechnology company’s stock valued at $562,000 after purchasing an additional 29,878 shares during the period. Finally, Polymer Capital Management US LLC bought a new stake in shares of Prothena during the 4th quarter valued at about $225,000. 97.08% of the stock is currently owned by institutional investors.

Prothena Trading Up 1.4%

PRTA opened at $9.59 on Monday. Prothena has a 12 month low of $4.32 and a 12 month high of $15.63. The business’s 50-day moving average price is $9.18 and its 200-day moving average price is $9.49. The company has a market cap of $516.23 million, a P/E ratio of -2.11, a P/E/G ratio of 0.63 and a beta of -0.24.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. Prothena had a negative net margin of 2,520.57% and a negative return on equity of 65.89%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.67 million. Equities research analysts forecast that Prothena will post -4.04 earnings per share for the current fiscal year.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.